Technology
Comparison with Conventional Testing
- Biallelic 1p del
1p deletions involving the CDKN2C gene are critical in defining risk in multiple myeloma. Though FISH is able to identify multiple myeloma 1p deletions, it is often challenging for it to detect bi-allelic deletions which indicate deletions of both copies of the gene. This is especially important when small portions of this gene are deleted. It is anticipated that almost *** percentage of bi allelic deletions may be missed by FISH based on available data.
- Small 17p dels
TP53 plays a major role in determining risk stratification in multiple myeloma. Historically only the 17p deletion has been used for this assessment . However PlasmaSEQ now classifies this at a dramatically improved resolution with the ability to detect small ‘multi-exonic’ deletions as well as the ability to detect single base pair level changes which have never been available before in a single assay.
- IgH breakpoint
For a long time, it has been well known that the exact breakpoint of the IgH rearrangement in translocations such as 4:14 and 14:16 affects outcomes. PlasmaSEQ finally provides this information for every patient while also helping researchers better determine how best to determine therapy and design clinical trials.
- Immunotherapy targets- BCMA, GPRC5D, APRIL (v2)
With the advent of immunotherapies, it is imperative that we have assays that can work for critical genes like BCMA, GPRC5D and APRIL. Plasmaseq V2 incorporates all of these targets and serves the critical need of being able to detect abnormalities in these genes at a very low plasma cell content.
